Considering the intricate interplay involving cytokine-mediated signaling, myeloid cell infiltration, and Pyk2/FAK activation within tumor cells, the decline in the Iba1 marker and the reduced infiltration of TIM observed in regrown tumors following PF-562271 treatment (Figure 3B–D) signifies that PF-562271 treatment not only hampers Pyk2/FAK signaling in tumor cells directly, but also leads to a reduction in infiltrating myeloid cells within the tumor. This evidence concerns the gene PTK2B and neoplasm.